Tissue diagnosis is important tool in diagnosis, monitoring, and management of different types of cancer conditions. Recognition of sign and symptoms of disease are done through biopsy, a process of taking sample from region of interest such as skin, tissue or tumor for further diagnosis. Biopsy are primarily done to look for cancer detection or to detect rejection of transplanted organ draft.

Biopsy is done to identify likely cause of cancerous and non-cancerous tissue, which are unable to detect through CT-scan or X-rays. Depending on area of sample collection various biopsy procedures are done such as endoscopic biopsy, bone marrow biopsy, skin biopsy, kidney biopsy, liver biopsy, and prostate biopsy. Furthermore biopsy can be done using needle biopsy, CT guided biopsy, Ultrasound biopsy, and surgical biopsy for the tissue diagnostic. According to the American journal of Nephrology, 2015, Australia has the highest numbers of annual renal biopsy rates (215 persons/million person/year) followed by the Finland (176 persons/million person/year) and U.S. (175 persons/million person/year). The increased numbers of biopsy procedure likely to fuel the growth of tissue diagnostic market, in near future.

Rising prevalence of different cancer incidences is major driving factor boosting the tissue diagnostic market. According to American cancer Society (ACS), 1.6 million new cases of cancer diagnosed in the U.S., in 2016. In addition, increase research funding in cancer treatment and growing healthcare expenditure likely to show gradual rise in tissue diagnostic market. National Cancer Institute, in 2015, spends US$ 4,480 million on various types of cancer research which includes breast cancer, colorectal cancer, cervical cancer, liver cancer, lung cancer, leukemia, ovarian cancer and uterine cancer.

Rise in the prevalence of cancer incidences to boost the tissue diagnostic market

According to the United States Cancer statistics report published in 2014 by Centers of Disease Control and Prevention (CDC), between 1999 and 2014, more than 1600 people a day, died due to the cause of cancer. Although screening tests helps to detect cancer condition at early stage, data from Healthy People 2020, an initiative form Department of Health and Human Services, reveals that screening rate is still below the national targets set. Combined data collected from CDC and National cancer institute (NCI) focus on the top 3 cancer incidences in male and female. In male prostate cancer incidence are higher, while in females breast cancer are most dominated, followed by lung and colon cancer respectively in both male and female.

New and advanced methods of tissue diagnosis favors the market growth

Innovation in tissue diagnostic process for the efficient diagnostic testing such as Fluorescence in situ hybridization (FISH), Immunohistochemistry (IHC) and In situ hybridization (ISH) raises the opportunity to grow tissue diagnostic market in future. In September 2017, researchers at the University of Texas, developed a new way of diagnosis by creating pen named as “MasSpec Pen”, which is handheld devices able to distinguish healthy tissue and tumor tissue in just 10 seconds, more than 150 times quicker than existing technology. These new tool provides improvement in cancer treatment and minimizes the chances of recurrence by offering precise diagnostic information, which eventually favors the growth in tissue diagnostic market.

Key players operated in the tissue diagnostic market are Biocare Medical, Agilent technologies, Thermo Fisher Scientific, Sigma-Aldrich, Roche Diagnostics, Danaher corp., Biogenex Laboratories, Life Technologies and Abbott laboratories.

Key Developments in Tissue Diagnostic Market

In May 2019, Roche launched VENTANA ROS1 (SP384) Rabbit Monoclonal Primary Antibody, an in vitro diagnostic ROS1 immunohistochemistry (IHC) assay. This assay detects the presence of ROS1 protein in tissue, and may be useful in identifying ROS1-positive cancer cases.
In August 2019, Lunaphore Technologies SA launched LabSat, a device to perform immunohistochemistry (IHC) tests for detecting specific cancer biomarkers in tissue samples from cancer patients.
In July 2018, Aquaro Histology launched Aquaro Wishbone microtome blade-handling tool. The device is used to remove and dispose of blades, as well as insert and align them without touching them.
In March 2017, Sakura Finetek USA, Inc. launched first and only Cryostat including Tissue-Tek Cryo3 Flex Cryostat Mohs. The new cryostat system is used to decrease the time to get complete sections, and in parallel to preserve valuable tissues.

Tissue diagnostic market taxonomy:

By Product Type:

Instruments

Tissue processors
Microtomes
Cryostats
Slide warmers
Paraffin dispenser
Biological microscopes
Embedded center modules
Strainers

Consumables

Stains
Paraffin
Cassettes
Autopsy & dissection
Slides

By Technology:

In situ hybridization
Digital pathology
Immunohistochemistry
Tissue microarray
Special staining

By Disease:

Breast cancer
Lymphoma cancer
Gastric cancer
Prostate cancer

By End user:

Research laboratories
Hospitals
Contract research organizations

About Author

Nikhilesh Ravindra Patel is a Senior Consultant with over 8 years of consulting experience. He excels in market estimations, market insights, and identifying trends and opportunities. His deep understanding of the market dynamics and ability to pinpoint growth areas make him an invaluable asset in guiding clients toward informed business decisions. He plays a instrumental role in providing market intelligence, business intelligence, and competitive intelligence services through the reports.